About

Dec 14-15, 2022    Dubai, UAE

International Conference on

Biosimilars and Generic Drugs

About Longdom Conferences

Longdom conferences hosting 200+ leading international conferences and virtual events annually. It is instrumental in bringing together experts and learners from all over the globe for mutual growth and effective research-oriented discussions. As per the present market demand and growth in the field of Biosimilars and Generic Drugs research, Longdom meetings is hosting its “International Conference on Biosimilars and Generic Drugs”. This is scheduled for December 14-15, 2022 in Dubai,UAE. The field of Biosimilars and Generic Drugs are one of the oldest scientific subjects, which are continuously evolving and have placed many landmarks in different research and development sectors. These fields are ecological science, agronomy, healthcare, drug discovery, food technology, and many other industrial areas. The Biosimilars Conference 2022 extends immense pleasure in inviting you to join us at this conference which will be focusing on the theme “New frontiers in Biosimilars Biologics”. We aim to engage, empower, evolve, and explore knowledge among attendees from all levels of scientific research on biosimilars. This Biosimilars and Generic Drugs conference will be focussing on the core knowledge and major advances in the rapidly emerging fields by attracting eminent scholars, experts, and professionals globally.

Why join LONGDOM conferences?

Understand the current state of research | Meet international colleagues and experts | Visit the exhibition of leading-edge technology | Engage with editors of the top journals in your field | Global networking and certification | Brand Launching and many more to explore

Who will be the participants?

Academic Deans and Directors | Professors and project leads | Postdocs and research scholars | Young scientists and students | CEOs/ CFOs/ Chairs/ Vice-Chairs | Marketing/ business and development teams | Experts who are keen-sighted for collaboration | Product designers and resolution workers | Business sales & services professionals | Associations and society members | Funding organizations & fundraisers

Important Scientific Sessions:

Session 1: Biosimilars

Biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Within the European Union, biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

Related  Biosimilars  Societies:

European society of Biosimilars | Biologics and Biosimilars - Gastrointestinal Society | American Society of Biosimilars | Scientific Societies | Arthritis Society of Biologics and biosimilars | Accenture Health Insurance Society of generic drugs | Leukemia and Lymphoma Society of drugs | Health Insurance Society of generic drugs Civil Society Over Generic drugs | Hitachi Health Insurance Society of generic drugs

Relevant Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 2: Biologics

A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. Biologic drugs include a wide variety of products derived from human, animal, or microorganisms by using biotechnology. Biologics are powerful medications that can be made of tiny components like sugars, proteins, or DNA or can be whole cells or tissues. These drugs also come from all sorts of living sources — mammals, birds, insects, plants, and even bacteria.

Best Biosimilars Societies:

Shiseido Health Insurance Society of generic drugs | Pharmaceutical Society of Singapore | Royal Society of Generic Drugs | Korean Society of Pharmaceutical Sciences and Technology | Pharmaceutical Industry and Society | International Society for Pharmaceutical Engineering | Pharmaceuticalization of Society | Strengthening pharma's contract with society | Royal Pharmaceutical Society | Pharmaceutical Society of Australia | R. v. Nova Scotia Pharmaceutical Society

Top Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 3: Successful biosimilar case studies

As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their go-to-market commercial strategies. Price is no longer the only driver and a hybrid approach is needed to forge new commercialisation strategies and partnerships. But what are the key reimbursement, physician education and regulatory obstacles that developers must take into account

  • Humira biosimilars facing a litigious battle
  • Biosimilar insulin–is it a sustainable business model?
  • Roche oncology strategy–biosimilars versus next generation products
  • Roche's RA franchise–is there room for tocilizumab biosimilars?
  • Pegfilgrastim biosimilars provide a 33% discount and rely on a branded launch strategy

 

Top  Biosimilars  Societies:

The International Society of Pharmacovigilance | The International Society for Pharmacoepidemiology | Pharmaceuticalization of Society in Context | Spanish Society of Rheumatology | The Portuguese Society of Rheumatology | American Society of Clinical Oncology | Society of Inflammation Research British Society of Gastroenterology consensus guidelines | American Thoracic Society | Reports Of Societies

Related  Biosimilars  Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 4: Analytical Strategies Biologics Biosimilars

Management of cGMP facility calls for a strict monitoring all factors including analytical strategies, formulation procedures, packaging etc. For biologic products establishing comparability and interchangeability is a big hurdle. For this purpose employment of suitable analytical approach, bioassay, protein analysis, potency testing, safety assurances are highly important. LC/MS analysis for biologic products, characterization of biologics, peptide mapping, Isoelectric Focusing and Capillary Isoelectric Focusing, SDS-PAGE, Thermal Analysis, Particulate Matter Analysis, Thermogravimetric Analysis are some methods commonly used for analysis of biologics and biosimilar products.

On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry.

  • Biosimilar multimodal techniques
  • Biosimilar bioanalytical methods
  • Bioassay for comparability and potency testing
  • Biosimilar LC/MS analysis for discovery, preclinical, and clinical programs
  • Biosimilar GMP protein analysis
  • Biosimilar electrophoresis

 

 List of  Biosimilars  Societies:

European society of Biosimilars | Biologics and Biosimilars - Gastrointestinal Society | American Society of Biosimilars | Scientific Societies | Arthritis Society of Biologics and biosimilars | Accenture Health Insurance Society of generic drugs | Leukemia and Lymphoma Society of drugs | Health Insurance Society of generic drugs | Civil Society Over Generic drugs | Hitachi Health Insurance Society of generic drugs | Shiseido Health Insurance Society of generic drugs

Different  Biosimilars  Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 5: Biosimilars in Oncology

FDA-approved biosimilars can be used to treat breast cancer, stomach cancer, colorectal cancer, and other cancers. They can also be used to treat side effects of cancer treatments, such as low white blood cell counts that increase the risk of infections.Biosimilars are potentially cheaper versions of other drugs that are being developed as treatments for cancer and other diseases. However, it is important to note that biosimilars are not defined by their cost alone, and in some cases, they may not be much cheaper than other drugs. Here, find out what biosimilars are, how they can be used to treat cancer, and how they can help lower the costs of cancer care.

Similar Biosimilars Societies:

Max Planck Society | Societies - Biomolecules | Society for Biomolecular Screening | American Society for Biochemistry and Molecular Biology | Society for Biomolecular Sciences (SBS) | Clubs & societies | School of Biotechnology and Biomolecular | Society of Biomolecular Imaging and Informatics Special Issue | Society for biomolecular screening origin and future role | Pandemics and Society

Similar Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 6: Clinical trials of Biologics Biosimilars

Clinical Trials is a multidisciplinary program with broad participation with members from around the globe focused on learning about clinical research and its advances. This is your best opportunity to reach the largest assemblage of participants from Clinical Trials community that is from academia, clinical research entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries. Clinical Trials  will discuss various disciplines involved in the pre-clinical research, conduct of clinical trials; it will educate health care researchers about design, operation, organizing, research computing, regulatory aspects and reporting of clinical trials. It promotes better understanding by the general public about the importance of clinical trials in prevention, diagnosis and treatment of disease.

  • Clinical trial market
  • Genome annotation
  • Single-nucleotide polymorphism
  • Gene and protein expression

 

Supporting  Biosimilars  Societies:

European society of Biosimilars | Biologics and Biosimilars - Gastrointestinal Society | American Society of Biosimilars | Scientific Societies | Arthritis Society of Biologics and biosimilars | Accenture Health Insurance Society of generic drugs | Leukemia and Lymphoma Society of drugs | Health Insurance Society of generic drugs | Civil Society Over Generic drugs | Hitachi Health Insurance Society of generic drugs | Shiseido Health Insurance Society of generic drugs

Best  Biosimilars  Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Session 7: Regulatory Approaches for Biosimilars

Biosimilars are the generic version of biological. It is the new buzz word in pharmaceutical industry. Biosimilars are highly similar to licensed reference product not withstanding minor differences in clinically inactive components; also there are no clinically meaningful differences between the biologicals and the reference product in terms of safety, purity, and potency. This track includes: Licensing of  biosimilars, Biosimilars regulation, Patent issues, BLA filing for biosimilars, Biosimilars regulatory prospects of BRIC countries, a paradigm of traditional generics to Biosimilars, Biowaiver approval for Biosimilars and other aspects of Biosimilar approvals. Biosimilars 2018 will provide an excellent and global opportunity to the scientists, partners and pharma leaders from Biopharmaceutical and Biotechnology industries to innovate and to explore the strategic market for Biosimilars and Biologics with a clear picture of the regulatory approach for biosimilars and biologics.

  • Licensing of biosimilars
  • Biosimilars regulation
  • BLA filing for biosimilars
  • Regulatory prospects of BRIC countries
  • A paradigm of traditional generics to biosimilars
  • Biowaiver approval for Biosimilars
  • Generic Biosimilars
  • BLA filing for biosimilars

 

Leading Biosimilars Societies:

Pharmaceutical Society of Singapore | Royal Society of Generic Drugs | Korean Society of Pharmaceutical Sciences and Technology | Pharmaceutical Industry and Society | International Society for Pharmaceutical Engineering | Pharmaceuticalization of Society | Strengthening pharma's contract with society | Royal Pharmaceutical Society | Pharmaceutical Society of Australia | R. v. Nova Scotia Pharmaceutical Society

Most common Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Track 8: Current Challenges in Developing Biosimilars

There are numerous obstacles that must be overcome in the creation of biologics. It is crucial that the correct scientific and strategic methods are followed for the effective development of follow-on-biologics in conjunction with the initial steps of biologic concepts, their considerations, and prerequisites for early clinical advances. Additionally, there is still a need to overcome difficulties in late clinical phases, medication safety considerations, and labelling regulations. A drug product must now be developed in accordance with the principle of quality by design (QbD). The numerous elements of the present issues in the development of biosimilars will be examined at this Eurobiosimilars conference.

Relevant Biosimilars Societies:

The International Society of Pharmacovigilance | The International Society for Pharmacoepidemiology | Pharmaceuticalization of Society in Context | Spanish Society of Rheumatology | The Portuguese Society of Rheumatology | American Society of Clinical Oncology | Society of Inflammation Research British Society of Gastroenterology consensus guidelines | American Thoracic Society | Reports Of Societies

Most Relevant Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Track 9: Chemical and Analytical Strategies for Biosimilars

A strict monitoring of all elements, such as analytical methods, formulation processes, packing, etc., is required for cGMP facility management. Establishing comparability and interchangeability for biologic goods is a significant challenge. Bioassay, protein analysis, potency testing, and safety guarantees are employed for this purpose and are of utmost importance. Some methods frequently used for analysis of biologics and Biosimilars products include LC/MS analysis for biologic products, peptide mapping, biologic characterization, isoelectric focusing and capillary isoelectric focusing, SDS-PAGE, thermal analysis, particulate matter analysis, and thermogravimetric analysis.

Core Biosimilars Societies:

The International Society of Pharmacovigilance | The International Society for Pharmacoepidemiology | Pharmaceuticalization of Society in Context | Spanish Society of Rheumatology | The Portuguese Society of Rheumatology | American Society of Clinical Oncology | Society of Inflammation Research British Society of Gastroenterology consensus guidelines | American Thoracic Society | Reports Of Societies

Broad Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Track 10: Biological Medicine

In addition to addressing the psychological, emotional, and physical elements of illness, biological medicine deals with the biology of the body and its innate capacity for recovery. Disease is a sign that the body's regulatory system is malfunctioning and has to be restored to its healthy, dynamic condition where the immune system is fully under control. Therefore, it seeks out the underlying reasons of the disease's presenting symptoms as well as the elements that led a person to develop a particular condition. These fundamental causes may be made up of a number of elements that have accumulated over time, such as trauma, exposure to bacteria or viruses, electromagnetic disturbances, family history, stress, environmental factors, heavy metals, dental issues, hyperacidity, and food allergies.

Few Global Biosimilars Societies:

European society of Biosimilars | Biologics and Biosimilars - Gastrointestinal Society | American Society of Biosimilars | Scientific Societies | Arthritis Society of Biologics and biosimilars | Accenture Health Insurance Society of generic drugs | Leukemia and Lymphoma Society of drugs | Health Insurance Society of generic drugs Civil Society Over Generic drugs | Hitachi Health Insurance Society of generic drugs

Most Popular Biosimilars Conferences:

Biosimilar Conferences | Biologics Meetings | International Conferences | Medical Meetings | Biosimilars and Biologics  Conferences | International Biologics Conferences | International Biosimilars Conferences

Market Analysis Report for Biosimilars Conference 2022

There are several copies of biologic drugs sold for many years in semi- and unregulated markets before the establishment of biosimilar guidelines by the European Medicines Agency (EMA).  The regulatory processes in these regions for the approval of these products are considerably less stringent compared to that of EMA.

Report Highlights:

The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate (CAGR) of 15% from 2019 through 2027.

  [email protected]
  [email protected]
  [email protected]
Speakers Interview